P30GM154635
Project Grant
Overview
Grant Description
Mentoring translational cancer research in Oklahoma - Abstract
Oklahoma faces a significant burden of cancer, with a high incidence and mortality rate.
The impact of cancer is particularly profound among diverse communities, including Native American populations, making it a pressing concern for our state.
Cancer poses a substantial challenge to the health and well-being of our residents, placing considerable social and economic strain on Oklahoma.
The primary objective of this COBRE is to advance cancer research in Oklahoma.
During Phase I and Phase II, our COBRE demonstrated remarkable progress.
Supported research project leaders secured competitive grants, including NIH R01 awards, Department of Defense grants, and esteemed foundation grants such as the American Cancer Society.
Of the total of 375 papers that were published with acknowledgment to our COBRE, COBRE research project leaders and pilot project leaders authored 246 papers, all of them benefiting from COBRE and COBRE-funded core support.
The COBRE-supported cores played a vital role in supporting multiple investigators, facilitating publications, and aiding in acquiring federal grants, enriching cancer research in Oklahoma.
Phase III seeks to build on this success, emphasizing sustainability and growth.
For Phase III of the COBRE program, our vision is to build upon our prior achievements, fostering sustainability and growth.
We remain dedicated to mentoring and supporting graduated research project leaders.
Our goal is to enhance core facilities to accommodate evolving cancer research needs, transitioning them into institutional cancer research cores.
Committed to fostering cross-disciplinary collaboration and translational research, Phase III COBRE will innovate through the pilot grants program.
These concerted efforts are poised to further advance cancer research in our region, moving us closer to the coveted designation of a comprehensive cancer center status for our NCI-designated cancer center.
The establishment of such a center will revolutionize cancer prevention and treatment, benefiting our community and beyond.
This Phase III COBRE marks a significant stride toward realizing our vision of a future free from the burden of cancer, where advanced research and improved clinical practices lead to better outcomes for all.
Oklahoma faces a significant burden of cancer, with a high incidence and mortality rate.
The impact of cancer is particularly profound among diverse communities, including Native American populations, making it a pressing concern for our state.
Cancer poses a substantial challenge to the health and well-being of our residents, placing considerable social and economic strain on Oklahoma.
The primary objective of this COBRE is to advance cancer research in Oklahoma.
During Phase I and Phase II, our COBRE demonstrated remarkable progress.
Supported research project leaders secured competitive grants, including NIH R01 awards, Department of Defense grants, and esteemed foundation grants such as the American Cancer Society.
Of the total of 375 papers that were published with acknowledgment to our COBRE, COBRE research project leaders and pilot project leaders authored 246 papers, all of them benefiting from COBRE and COBRE-funded core support.
The COBRE-supported cores played a vital role in supporting multiple investigators, facilitating publications, and aiding in acquiring federal grants, enriching cancer research in Oklahoma.
Phase III seeks to build on this success, emphasizing sustainability and growth.
For Phase III of the COBRE program, our vision is to build upon our prior achievements, fostering sustainability and growth.
We remain dedicated to mentoring and supporting graduated research project leaders.
Our goal is to enhance core facilities to accommodate evolving cancer research needs, transitioning them into institutional cancer research cores.
Committed to fostering cross-disciplinary collaboration and translational research, Phase III COBRE will innovate through the pilot grants program.
These concerted efforts are poised to further advance cancer research in our region, moving us closer to the coveted designation of a comprehensive cancer center status for our NCI-designated cancer center.
The establishment of such a center will revolutionize cancer prevention and treatment, benefiting our community and beyond.
This Phase III COBRE marks a significant stride toward realizing our vision of a future free from the burden of cancer, where advanced research and improved clinical practices lead to better outcomes for all.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Oklahoma City,
Oklahoma
73104
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 200% from $1,072,500 to $3,217,500.
University Of Oklahoma was awarded
Advancing Cancer Research in Oklahoma - Phase III COBRE
Project Grant P30GM154635
worth $3,217,500
from the National Institute of General Medical Sciences in August 2024 with work to be completed primarily in Oklahoma City Oklahoma United States.
The grant
has a duration of 4 years 10 months and
was awarded through assistance program 93.859 Biomedical Research and Research Training.
The Project Grant was awarded through grant opportunity Limited Competition: Centers of Biomedical Research Excellence (COBRE) (Phase 3) - Transitional Centers (P30 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 7/6/26
Period of Performance
8/10/24
Start Date
6/30/29
End Date
Funding Split
$3.2M
Federal Obligation
$0.0
Non-Federal Obligation
$3.2M
Total Obligated
Activity Timeline
Transaction History
Modifications to P30GM154635
Additional Detail
Award ID FAIN
P30GM154635
SAI Number
P30GM154635-3048453542
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NS00 NIH National Institute of General Medical Sciences
Funding Office
75NS00 NIH National Institute of General Medical Sciences
Awardee UEI
GY8NMUZQXVS7
Awardee CAGE
4B862
Performance District
OK-05
Senators
James Lankford
Markwayne Mullin
Markwayne Mullin
Modified: 7/6/26